Morgan Lewis

Life Sciences Transactions Selected Representations

For More Information

Read the brochure

Emerging Business Tools

visit the Entrepreneur Resource Headquarters

Related Publications

06/19/08 From Europe and Japan to the U.S.: Build or Buy?, presented at the 2008 BIO International Convention, San Diego, CA
05/24/05 Pharmaceutical Industry Mergers: Anticipating Antitrust Issues and Surviving the Investigation, presented at the American Conference Institute In-House Counsel Forum on Pharmaceutical Antitrust, Washington, D.C.
View all publications

Related News

09/16/14 Morgan Lewis Tops BioPharm Insight Second-Quarter League Tables
Morgan Lewis is pleased to announce that its Life Sciences and Healthcare practice has again placed among the top firms in BioPharm Insight ’s quarterly league tables.
04/11/13 Morgan Lewis Advises MEI Pharma on $15.2 Million Registered Offering of Common Stock
Morgan Lewis served as legal adviser to MEI Pharma, Inc. on registered offering of common stock.
10/29/10 Morgan Lewis Advises Safeguard Scientifics on $587 Million Sale of Clarient to GE Healthcare
In a transaction valued at $587 million, Clarient, Inc. has agreed to be acquired by GE Healthcare.
View all news

Honors

BioPharm Insight 2013 Q3

  • Ranked 1st – Legal Advisors to Biotech and Pharma Licensing Agreements: Asia-Pacific – Based on Value
  • Ranked 2nd – Legal Advisors to Biotech and Pharma Licensing Agreements: Asia-Pacific – Based on Volume
  • Ranked 3rd – Legal Advisors to Biotech and Pharma Licensing Agreements: Europe – Based on Value
  • Ranked 8th – Legal Advisors to Biotech and Pharma Licensing Agreements: Europe – Based on Volume
  • Ranked 7th – Global League Table of Legal Advisors to Biotech and Pharma Licensing Agreements – Based on Value
  • Ranked 9th – Global League Table of Legal Advisors to Biotech and Pharma Licensing Agreements – Based on Volume
  • Ranked 10th – Legal Advisors to Biotech and Pharma Licensing Agreements: North America – Based on Value
  • Ranked 10th – Legal Advisors to Biotech and Pharma Licensing Agreements: North America – Based on Volume

Our Life Sciences Transactions Practice assists clients in structuring, negotiating and implementing merger & acquisition, joint venture, strategic alliance, corporate partnering, licensing, financing and outsourcing transactions to help them achieve their business goals. Our ability to also provide the life sciences regulatory, scientific and litigation assessment components necessary to a transaction (including intellectual property, FDA/healthcare regulatory, product liability, outsourcing, tax, antitrust, labor and employment, employee benefits and real estate), uniquely positions us to successfully complete transactions in a coordinated and efficient manner. Representative transactions include:

Mergers & Acqusitions

  • Prospira PainCare Holdings in its acquisition of Pain Control Associates
  • Mylan in its $1.6 billion acquisition of Agila Specialties
  • Italfarmaco in its acquisition of 30% of Women's Choice Pharmaceuticals
  • Perrigo Company in its $160 million acquisition of Velcera
  • BioClinica in its $123 million sale to JLL Partners
  • Prospira PainCare in the acquisition of medical assets and health care business assets from Florida Pain, National Pain Institute, Florida Pain & Rehabilitation Institutes, National Surgical Centers of America, and National Pain Research Institute
  • SDIX in the $13.5 million sale of the assets of its food safety and genetically modified ingredient testing business to Romer Labs
  • Pulse Equity Partners in the acquisition of practice assets from Prospira PainCare Holdings
  • Perrigo Company in its $285 million acquisition of Sergeant's Pet Care Products
  • The Spine Center of Southeast Georgia in its sale to Prospira PainCare
  • MEI Pharma in its acquisition from S*BIO of the rights to Pracinostat, a clinical stage oncology drug
  • Octagon Research Solutions in its sale to Accenture
  • LifeNet Health in its acquisition of Northwest Tissue Services from Puget Sound Blood Center
  • Abbott in its acquisition of Action Pharma
  • Sun Capital Partners in its acquisition of Cornerstone Research & Development from Mitsui
  • FMC Corporation in its acquisition of the Rovral® iprodine and Sportak® prochloraz brand families from Bayer CropScience
  • Concordia Pharmaceuticals in the sale to Kadmon Corporation of substantially all its assets, including its rights to the cancer drug Salirasib
  • Diversified Service Options, a wholly-owned subsidiary of Blue Cross and Blue Shield of Florida and the holding company for First Coast Service Options, in its acquisition of Highmark Medicare Services, a subsidiary of Highmark
  • Independence Blue Cross in its acquisition of AmeriHealth Mercy Family of Companies
  • AxoGen Corporation in its reverse triangular merger with LecTec Corporation
  • Perrigo Company in the sale of certain marketed pharmaceutical products to Watson Pharmaceuticals
  • Alacer Biomedical in its sale to Allergan
  • Orchid Cellmark in its sale to LabCorp for $85.4 million
  • OnPoint Medical Diagnostics in its reverse merger with Vertical Health Solutions
  • Galen Partners in its purchase of a controlling equity stake in Cambrooke Foods, a pharma foods company
  • Embrella Cardiovascular in its $43 million sale to Edwards Life Sciences
  • Axcan Pharma in its sale of the pharmaceutical products, Photofrin and Photobarr, to Pinnacle Biologics
  • ARAMARK Healthcare in its acquisition of Masterplan
  • Perrigo in its $540 million acquisition of Paddock Laboratories
  • medSage in its sale to Respironics, a division of Philips Electronics
  • Eurand in its $538 million sale to Axcan Holdings
  • Sofinnova Partners in the sale of Preglem to Gedeon Richter for €337 million
  • BMP Sunstone in its sale to sanof-aventis for $526 million
  • Safeguard Scientifics in the sale of its partner company Clarient to GE Healthcare for $587 million
  • Solstice Neurosciences in its sale to US WorldMeds for $35 million
  • InfuSystem Holdings in its acquisition of First Biomedical for $17.2 million
  • ViroPharma in its ₤20 million acquisition of Auralis
  • Valeant Pharmaceuticals in its acquisition of Aton Pharma for $318 million
  • BioClinica in its acquisition of TranSenda International
  • Biovail in its acquisition of certain AMPAKINE® compounds and associated intellectual property from Cortex Pharmaceuticals
  • Perrigo Company in its acquisition of PBM Products for $808 million
  • The investors of Novexel including Sofinnova Partners, Atlas Venture, Novo AS, Edmond de Rotschild Investment Partners, Daiwa SMBC Capital Co, NeoMed, Abingworth and Goldman Sachs in the sale of Novexel to AstraZeneca for $505 million
  • BioClinica in its acquisition of Tourtellotte Solutions and CardioNow
  • Medical Imaging Holdings in its acquisitions of Sonora Medical Systems, Barrington Medical Imaging, and Echoserve
  • Abingworth, Crédit Agicole Private Equity, Fobion, Gimv, Sofinnova, Veslius, and Wellcome Trust, as investors of Fovea Pharmaceuticals, in its $562 million sale to Sanofi-Aventis
  • Leo Pharma in its re-acquisition of U.S. rights to its topical psoriasis treatments from Warner Chilcott for approximately $1 billion
  • PeriGen in is acquisition of LMS Medical Systems
  • Pierrel Research in its acquisition of Encorium Group
  • Chiesi Farmaceutici in its $70 million strategic transaction with Cornerstone Therapeutics
  • Biovail Laboratories International SRL in its $510 million acquisition from GlaxoSmithKline of U.S. rights for Wellbutrin XL, approved for major depressive disorder and seasonal affective disorder and originally developed by Biovail
  • Sekisui America Corporation in its $25.5 million acquisition of American Diagnostica
  • CardioNet in its $14 million acquisition of Biotel
  • Bio-Imaging Technologies in the sale of its CapMed Division to Metavante Technologies
  • GPC Biotech in its merger Agennix to form a new publicly listed company
  • Lundbeck in its acquisition of Ovation Pharmaceuticals for $600 million and up to $300 million in contingent payments
  • NexMed in its sale of the U.S. rights for its topical alprostadil erectile dysfunction treatment (Alprox) to partner, Warner Chilcott
  • PharmaNet Development Group in its sale to JLL Partners for $250 million
  • Meridian Healthcare Group in its sale to Lincare for $44 million
  • United Drug plc in the acquisition of The Specials Laboratory for $38 million
  • Valeant Pharmaceuticals in the acquisition of Dow Pharmaceutical Sciences for $285 million
  • RecoverCare in its acquisition of T.H.E. Medical
  • Biovail in its acquisition of Prestwick Pharmaceuticals for $100 million
  • Neose Technologies in its $43 million sale to Novo Nordisk and BioGenix
  • Nanogen in its acquisition by Elitech Group
  • Health Care Service Corporation in the acquisition of MEDecision
  • Eli Lilly in the sale for $50 million of a drug development unit to and long-term strategic $1.6 billion services agreement with Covance
  • PhotoMedex in its $13 million acquisition of Photo Therapeutics
  • Sekisui Chemical Co. in its acquisition of XenoTech valued at $50 million
  • Sharp Corporation in its $99 million sale to United Drug plc
  • Barrier Therapeutics in its $148 million sale to Stiefel Laboratories
  • Catalent Pharma Solutions in the sale of its New Mexico pharmaceutical laboratory to Oso Biopharmaceuticals Manufacturing
  • EP MedSystems in its acquisition by St. Jude Medical for $92.1 million
  • Bio-Imaging Technology in its acquisition of Phoenix Data Systems for $22 million
  • Cytogen in its acquisition by EUSA Pharma for $22.6 million
  • AmerisourceBergen in its acquisition of Bellco Drug Corp for $190 million
  • Oncology Therapeutics Network (OTN), a portfolio company of One Equity Partners, in its sale to McKesson for $575 million
  • New Brunswick Scientific in its sale to the Eppendorf Group for $110 million
  • Perrigo Company in its acquisition of Glades Pharmaceuticals
  • Wockhardt Limited in its acquisition of Radiant Research
  • VIASYS Healthcare in its sale to Cardinal Health for $1.5 billion
  • Merck in its divestiture of several marketed products to Iroko Pharmaceuticals
  • Sierra Health Services in its sale to UnitedHealth Group for $2.6 billion
  • Bio Imaging Technology in its acquisition of Theralys SA
  • BioRexis Pharmaceutical in its acquisition by Pfizer
  • Cytogen in the sale of its 50% joint venture interest in PSMA Development Company LLC to Progenics
  • CMS Private Equity Fund in its acquisition of Med-Dispense
  • Provid Pharmaceuticals in its acquisition of Tripos Discovery Research
  • Lundbeck in its acquisition of Saegis Pharmaceuticals
  • Sun Capital Partners in its $17 million acquisition of Respiratory Distributors
  • HAPC in its acquisition of InfuSystem for $140 million
  • GNI Ltd. in its acquisition of a controlling interest in Shanghai Genomics in part through the required auction process to purchase the shares of state-owned entities
  • United Drug plc in its combined $50 million acquisition of Endoscopy Limited
  • OTN in its acquisition of the oncology distribution unit of Cardinal Health
  • Nanogen its acquisition of Amplimedical S.p.A.
  • Meridian Health Care Group and subsidiary Primedica in the acquisition of Symphony Respiratory Care
  • Schering-Plough in its acquisition of Bayer AG’s primary care pharmaceutical product business in the United States and related strategic alliances on oncology products and on Zetia® in Japan
  • Med-Design in its sale to Specialized Health Products International
  • Nanogen in its acquisition of Spectral Diagnostics-Rapid
  • Laureate Pharma in its acquisition by Discovery Pharmaceuticals
  • Biophan Technologies in its acquisition of interest in Myotech
  • Duramed Pharmaceuticals in its $156 million acquisition of Mircette desogestrel tablets from Organon International
  • Cerenis Therapeutics in its $30 million sale to Sifinnova, Healthcap, Alta Partner, EDF, and NIF, a consortium of French and U.S. venture capital firms
  • excelleRX in its acquisition by Omnicare
  • InKine Pharmaceutical in its sale to Salix Pharmaceuticals
  • United Drug plc in its acquisitions of In2Focus Development Services, TD Packaging, and Presearch Limited
  • Femme Pharma Global Healthcare in its divestiture of its Danazol® product to KV Pharmaceuticals
  • One Equity Partners in its acquisition from Bristol-Myers Squibb of Oncology Therapeutics Network
  • Biovail in its more than $100 million divestiture of its Teveten® and Teveten HCT® products and sale of the marketing rights of its Cardizem®LA product to Kos Pharmaceuticals
  • Viscogliosi Brothers in its acquisition of Fixano France
  • Smiths Group plc in its $925 million acquisition of Medex
  • Perrigo Company in its $818 million cash and stock acquisition of Agis Industries Ltd.
  • Closure Medical in its $421 million acquisition by Johnson & Johnson
  • Viasys Holdings in its acquisition of the medical division of Oxford Instruments plc for $24 million
  • Barrier Therapeutics in its acquisition of the rights to Solage topical solution from Moreland Enterprises
  • Sanofi-Aventis in the divestiture of Campto® to Pfizer
  • Nanogen in its acquisition of SynX
  • Esperion in its acquisition by Pfizer for $1.3 billion
  • United Drug plc in its $11 million acquisition of Mantis Surgical Limited
  • Cell Pathways in its stock-for-stock acquisition by OSI Pharmaceuticals
  • 3-Dimensional Pharmaceuticals in its acquisition by Johnson & Johnson
  • Enzon in its acquisition of Abelcet® product rights and related manufacturing facility and other assets from Elan for $370 million
  • Pharmacia in the divestiture of its late stage compound to Nastech in connection with its then proposed merger with Pfizer
  • Principia in its stock-for-stock acquisition by Human Genome Sciences
  • Cephalon in its $444 million stock-for-stock acquisition of Anesta
  • AmeriHealth Caritas in the acquisition of the Medicaid managed care business of DC Chartered Health Plan
  • BTG in the $180 million acquisition of EKOS Corporation
  • Senhwa Biosciences in its acquisition of assets related to cancer treatment programs from Cylene Pharmaceuticals
  • AmerisourceBergen in the $308 million sale of its AndersonBrecon business to Frazier Healthcare
  • Takeda Pharmaceutical Company in its $250 million acquisition of Inviragen
  • Auxilium Pharmaceuticals in its $585 million acquisition of Actient Holdings

Joint Ventures & Strategic Alliances

  • Takeda in its collaboration with Resolve Therapeutics to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases
  • Lundbeck in its agreement with Otsuka Pharmaceutical to promote the drug Abilify in 14 European countries
  • Lundbeck in its up to $825 million collaboration with Otsuka Holdings to develop an experimental Alzheimer's treatment
  • NPS Pharmaceuticals in its termination and transition services agreement with Takeda to re-acquire certain rights to develop and sell Revestive and Preotact
  • Oncobiologics in its agreement with Viropro to co-manage Viropro's Penang Malaysia Alpha Biologics biomanufacturing subsidiary and to grant. Viropro the rights to manufacture Oncobiologics' six monoclonal antibody biosimilar products for commercialization by Oncobiologics in certain emerging market countries, and by Viropro in Malaysia
  • Merck Serono in its option and license agreement valued up to $225 million with Opexa Therapeutics for the development and commercialization of TcelnaTM, a T-cell therapy for those suffering from multiple sclerosis
  • VaxInnate in its licensing agreement with Emergent BioSolutions which gives Emergent the exclusive right to manufacture and sell VaxInnate's pandemic influenza vaccine candidate in the U.S.
  • GSK in its up to $335 million research collaboration and license agreement with MD Anderson Cancer Center through its new Institute for Applied Cancer Science (IACS) to develop new therapeutic antibodies that promote an immune system attack against cancer
  • Prosetta Antiviral in its strategic alliance with Bristol-Myers Squibb to further discover and develop select drug candidates representing new, novel classes of antiviral drugs, with a particular initial focus on AIDS
  • Merck in its development and commercialization agreement with Ambrx to design and develop rationally optimized biologic drug conjugates
  • PDS Biotechnology in a licensing agreement in which Merck KGaA will use PDS' Versamune platform nanotechnology in two of Merck's investigational antigen-specific cancer immunotherapies
  • Merck Serono in its development, manufacturing and commercialization collaboration with Dr. Reddy's Laboratories for a portfolio of biosimilar compounds in oncology primarily focused on monoclonal antibodies
  • Enzon Pharmaceuticals in its strategic research, development and licensing collaboration with Zhejiang Hisun Pharmaceuticals for Enzon's PEGylation lnker technology, and Hisun's acquisition of exclusive development and commercialization rights in China to PEG-SN38, a PEGylated anti-cancer drug
  • Abbott in its licensing agreement with Zealand Pharma for the development and commercialization of AP214
  • GlaxoSmithKline in the formation with Johnson & Johnson and Index Ventures of a $200 million fund to invest in early stage biotechnology companies
  • Auxilium Pharmaceuticals in its up to $70 million collaboration with Actelion for Xiaflex® in Canada, Mexico, Brazil and Australia
  • Merck in a joint venture with Merck Sharp & Dohme Farmacêutica and Supera Farma Laboratorios in the formation of Supera RX Medicamentos, which will promote and sell pharmaceutical products from Merck, Cristália and Eurofarma in the Brazilian retail sector
  • Shire in its co-development and co-commercialization agreement with Shionogi for certain of Shire's ADHD medicines in Japan
  • Lundbeck in its up to $1.8 billion co-development and co-commercialization global alliance with Otsuka Pharmaceutical for up to five innovative psychiatric and neuroscience products worldwide
  • Antares Pharma in its licensing agreement with Watson Pharmaceuticals to commercialize Antares' topical oxybutynin gel product in the U.S. and Canada
  • BTG in its acquisition of the U.S. commercial rights to Wellstat Therapeutics Corporation's product candidate uridine triacetate
  • Abbott in its license agreement with Biotest AG to obtain the rights to develop and commercialize a novel anti-CD4 antibody (BT-061) for the treatment of autoimmune diseases
  • Merck in its agreement with Roche through their respective subsidiaries, to improve treatment, diagnosis, and awareness of chronic hepatitis C infection in developed and emerging markets
  • Eli Lilly in its transfer of US rights to sepsis drug Xigris® to BioCritica, a newly created biotech company jointly owned by Lilly, Care Capital and NovaQuest Capital
  • ViroPharma in its global collaboration and licensing agreement for the subcutaneous combination of Cinryze® (C1 esterase inhibitor [human]) with Halozyme Therapeutics' recombinant human hyaluronidase enzyme (rHuPH20) EnhanzeTM technology
  • Merck in its joint venture with Sun Pharmaceutical Industries for innovative formulations
  • Lundbeck in its donation together with Novartis of their rights to compound Lu AE58479 for SSADH deficiency to the National Institutes of Health
  • Auxilium Pharmaceuticals in its up to $262 million development, commercialization and supply collaboration with Asahi Kasei for Xiaflex® in Japan
  • Takeda in its up to $750 million development and commercialization collaboration with Intra-Cellular Therapies on selective phosphodiesterase type 1 (PDE1) inhibitors for cognitive impairment associated with schizophrenia
  • Lundbeck in its commercial rights agreement with Cephalon to register and commercialize several Cephalon products including Fentora, Provigil, Treanada, Trisenox, Myocet and Nuvigil in Canada and Latin America
  • Lundbeck in its drug discovery collaborations with Zenobia Therapeutics and Vernalis plc for inhibitors for LRRK2
  • Invida Group in its exclusive licensing and distribution collaboration with Orexo AB covering the Pacific region for AbstralTM
  • Lundbeck in its distribution agreement with Merck to acquire the rights outside the U.S., China and Japan to Asenapine (Sycrest), a drug approved for bipolar disorder
  • Lundbeck in its development and commercialization collaboration agreement with Kyowa Hakko Kirin relating to adenosine A2A antagonist products outside of Japan and the Asia region for all fields, including Parkinson's disease
  • Onyx Pharmaceuticals in its more than $300 million development and commercialization collaboration with Ono Pharmaceutical for Carfilzomib and ONX-0912 in oncology indications in Japan
  • Concordia Pharmaceuticals in its licensing agreement with Ono Pharmaceutical to develop and commercialize salirasib, an agent for the treatment of pancreatic, non-small cell lung and colorectal cancers, in Japan
  • Diamyd Medical AB in its up to $625 million license, development, and commercialization agreement with Ortho-McNeil-Janssen Pharmaceuticals focused on GAD65 antigen-based therapy for the treatment and prevention of type 1 diabetes and associated conditions
  • Biovail in its license agreement with Kyowa Hakko Kirin to acquire the U.S. and Canadian rights to commercialize products containing istradefylline
  • GlaxoSmithKline in its up to $1.58 billion antisense drug collaboration with Isis Pharmaceuticals for the development and commercialization of therapeutics for rare and infectious diseases
  • Smiths Detection in its collaboration with Novartis Diagnostics relating to Smiths' Bio-Seeq platform and LATE-PCR technology for use in a range of point-of-care diagnostic tests
  • Biovail in its development and commercialization agreement with Alexza Pharmaceuticals
  • NovaDel Pharma in negotiating its license agreement with Mist Acquisition to manufacture and commercialize NitroMist
  • Biovail in its acquisition of the U.S. and Canadian rights to develop and commercialize Santhera Pharmaceuticals' treatment of Dyskinesia in Parkinson's Disease
  • Shire in its multimillion dollar transformative manufacturing arrangement, whereby it transitioned the manufacture of several specialty pharmaceutical products to DSM Pharmaceuticals
  • Biovail in its up to $395 million collaboration with Acadia Pharmaceuticals to develop and commercialize Pimavanserin for neurological and psychiatric indications
  • Shire in its co-promotion agreement with GlaxoSmithKline for Shire's product VyvanseTM
  • Morphotek, and parent company Eisai, in a discovery, development, and commercialization collaboration between Morphotek and Human Genome Sciences for therapeutic monoclonal antibodies for oncology and immunology
  • Biovail in its supply agreement with sanofi-aventis U.S. for the marketing and distribution of the drug Aplenzin in the United States and Puerto Rico
  • Lonza Group in its joint venture with Teva Pharmaceutical Industries to develop, manufacture, and market a portfolio of biosimilars
  • Abeille Pharmaceuticals in its license agreement with Strakan International Limited relating to Abeille's AB-1001 product
  • Eurand in its license and supply agreement with Daewoong Pharmaceuticals relating to Eurand's novel extended-release (ER) formulation of the muscle relaxant Cyclobenzaprine HCl 
  • Auxilium Pharmaceuticals in its up to $485 million development, commercialization, and supply collaboration with Pfizer for XiaflexTM in Europe and Eurasia 
  • Profectus BioSciences in the worldwide acquisition and license of Wyeth's therapeutic and prophylactic DNA and vectored vaccine programs for HIV, HCV, HPV, HSV, and Malaria
  • Merck in its commercialization agreement with Gilead Sciences relating to Atripla
  • Lumiphore in its agreement with Algeta for worldwide license to Lumiphore's patented chelator technology to be used for cancer therapeutics